CA2298737A1 - Utilisation de l'antagoniste tgf-.beta. pour inhbiber la formation de cellules cancereuses en progression - Google Patents

Utilisation de l'antagoniste tgf-.beta. pour inhbiber la formation de cellules cancereuses en progression Download PDF

Info

Publication number
CA2298737A1
CA2298737A1 CA 2298737 CA2298737A CA2298737A1 CA 2298737 A1 CA2298737 A1 CA 2298737A1 CA 2298737 CA2298737 CA 2298737 CA 2298737 A CA2298737 A CA 2298737A CA 2298737 A1 CA2298737 A1 CA 2298737A1
Authority
CA
Canada
Prior art keywords
tgf
beta
antagonist
cells
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2298737
Other languages
English (en)
Inventor
Manikkam Suthanthiran
Minoru Hojo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Priority to CA 2298737 priority Critical patent/CA2298737A1/fr
Publication of CA2298737A1 publication Critical patent/CA2298737A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
CA 2298737 2000-02-10 2000-02-10 Utilisation de l'antagoniste tgf-.beta. pour inhbiber la formation de cellules cancereuses en progression Abandoned CA2298737A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2298737 CA2298737A1 (fr) 2000-02-10 2000-02-10 Utilisation de l'antagoniste tgf-.beta. pour inhbiber la formation de cellules cancereuses en progression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2298737 CA2298737A1 (fr) 2000-02-10 2000-02-10 Utilisation de l'antagoniste tgf-.beta. pour inhbiber la formation de cellules cancereuses en progression

Publications (1)

Publication Number Publication Date
CA2298737A1 true CA2298737A1 (fr) 2001-08-10

Family

ID=4165323

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2298737 Abandoned CA2298737A1 (fr) 2000-02-10 2000-02-10 Utilisation de l'antagoniste tgf-.beta. pour inhbiber la formation de cellules cancereuses en progression

Country Status (1)

Country Link
CA (1) CA2298737A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005050200A2 (fr) * 2003-11-13 2005-06-02 Genentech, Inc. Dosages de criblage et procedes de traitement de tumeur

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005050200A2 (fr) * 2003-11-13 2005-06-02 Genentech, Inc. Dosages de criblage et procedes de traitement de tumeur
WO2005050200A3 (fr) * 2003-11-13 2005-12-01 Genentech Inc Dosages de criblage et procedes de traitement de tumeur

Similar Documents

Publication Publication Date Title
JP6748155B2 (ja) 線維症抑制活性を有するペプチド及びこれを含む組成物
EP2744829B1 (fr) Anticorps dirigés contre la molécule d'adhésion cellulaire associée à l'antigène carcinoembryonnaire (ceacam)
JP4384852B2 (ja) 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
KR101236224B1 (ko) 항 이피캠 면역글로불린
EP2822573B1 (fr) Traitement contre le cancer
KR20130028050A (ko) 유방암을 치료하는 방법
MXPA02008465A (es) Metodo de tratamiento del cancer con agentes anti-neurotrofina.
US8912011B2 (en) Antibodies to sulfated carbohydrates
KR20100016237A (ko) 항-ＥｐＣＡＭ 항체 및 이의 용도
CN103201290A (zh) S100a4抗体及其治疗用途
CN108367068B (zh) 用于治疗白血病的抗-s100a8
US6458767B1 (en) Use of peptides inhibitory for thrombospondin dependent TGF-β activation in the treatment of kidney disease
CA2581787A1 (fr) Utilisation d'antagonistes du tgf-b pour limiter la nephrotoxicite d`agents immunosuppresseurs
KR20090122911A (ko) Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
KR20140075768A (ko) 다발성-골수종 관련 질환 치료에 사용되는 항-icam-1 항체
WO2005018671A1 (fr) Inhibiteur de metastase cancereuse
ITRM20090081A1 (it) Uso di inibitori della proteina 90k per la preparazione di un medicamento per la cura o prevenzione dei tumori.
US20040197333A1 (en) Use of TGF-beta antagonists to inhibit tumor cell formation or progression
EA023331B1 (ru) Композиции антител к vegfr-3
EP2984108B1 (fr) Anticorps anti-s100a7 pour le traitement et le diagnostic de cancer
EP0835662A2 (fr) Médicament pour le traitement du cancer
CA2298737A1 (fr) Utilisation de l'antagoniste tgf-.beta. pour inhbiber la formation de cellules cancereuses en progression
Custer et al. Characterization of an antibody that can detect the Kai1/CD82 murine metastasis suppressor
EP1544213A1 (fr) Utilisation de ligands de l'antigène CD52 pour le traitement de tumeurs solides et des cancers de type osseux
UA73300C2 (en) Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis

Legal Events

Date Code Title Description
FZDE Dead